Summary
This Form 8-K filing by Gilead Sciences, Inc. (GILD) on August 3, 2009, primarily reports on key personnel changes within the company. The most significant updates for investors relate to the appointment of a new director and a promotion within the executive team, along with the associated compensation adjustments. These changes are being disclosed as per SEC regulations to ensure transparency regarding corporate governance and executive compensation. The filing details the election of Kevin E. Lofton to the Board of Directors, where he will also serve on the Compensation Committee. His compensation includes pro-rated equity grants (stock options and restricted stock units) and a cash retainer. Additionally, Gregg H. Alton has been promoted to Executive Vice President, Corporate and Medical Affairs. His compensation package has been updated with an increased base salary, new stock options with a defined vesting schedule, and an enhanced target bonus award for the remainder of 2009.
Key Highlights
- 1Gilead Sciences appointed Kevin E. Lofton to its Board of Directors, effective July 29, 2009.
- 2Mr. Lofton will also serve on the Board's Compensation Committee.
- 3Kevin E. Lofton will receive pro-rated equity grants, including options for 6,604 shares and restricted stock units for 2,359 shares, along with a pro-rated cash retainer of $87,712.
- 4Gregg H. Alton was promoted to Executive Vice President, Corporate and Medical Affairs, effective July 29, 2009.
- 5Mr. Alton's base salary increased from $540,000 to $590,000.
- 6Mr. Alton was granted 45,000 stock options with a 10-year term and a specific vesting schedule (20% after one year, then quarterly over four years).
- 7Mr. Alton's target bonus award for the remainder of 2009 increased from 55% to 60% of his base salary.